Clinical Trial Detail

NCT ID NCT01498484
Title Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Atara Biotherapeutics
Indications

Advanced Solid Tumor

nasopharynx carcinoma

lymphoma

leiomyosarcoma

Therapies

EB-VST cells

Age Groups: adult child senior

No variant requirements are available.